The Utility of the KBCS Guidelines for realistic and useful guidelines. CONCLUSION For the progress of the KBCCPG, the guideline committee should attempt to reinforce all courses of guideline develop- ment with several elements including, data from clinical trials of Korean breast cancer patients, securing a multidisciplinary approach, development of consistent and reasonable processes in each step of the revision of the guideline, and induction of liberal scientific and ethical discussion about all issues with all KBCS members. CONFLICT OF INTEREST The authors declare that they have no competing interests. REFERENCES 1. AmericanAcademy of Pediatrics Steering Committee on Quality Im- provement and Management. Classifying recommendations for clinical practice guidelines. Pediatrics 2004;114:874-7. 2. CarlsonRW, McCormick B. Update: NCCN breast cancer clinical prac- tice guidelines. J Natl Compr Canc Netw 2005;3 Suppl 1:S7-11. 3. BeversTB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 2009;7:1060-96. 4. DelaneyA, Bagshaw SM, Ferland A, Laupland K, Manns B, Doig C. The quality of reports of critical care meta-analyses in the Cochrane 243 Database of Systematic Reviews: an independent appraisal. Crit Care Med 2007;35:589-94. 5. HussainT, Michel G, Shiffman RN. How often is strength of recom- mendation indicated in guidelines? Analysis of the Yale Guideline Recommendation Corpus. AMIA Annu Symp Proc 2008:984. 6. GuyattGH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. 7. MoranCJ, Kell MR, Kerin MJ. The role of sentinel lymph node biopsy in ductal carcinoma in situ. Eur J Surg Oncol 2005;31:1105-11. 8. ZavagnoG, Carcoforo P, Marconato R, Franchini Z, Scalco G, Burelli P, et al. Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. BMC Cancer 2005;5:28. 9. HoussamiN, Ciatto S, Macaskill P, Lord SJ, Warren RM, Dixon JM, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;26:3248-58. 10. LehmanCD, DeMartini W, Anderson BO, Edge SB. Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Canc Netw 2009;7:193-201. 11. HannaWM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol 2006;19:481-7. 12. CardinaleD, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic im- plications of troponin I evaluation. J Clin Oncol 2010;28:3910-6. 13. GoldhirschA, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Pri- mary Therapyof Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47. http://dx.doi.org/10.4048/jbc.2012.15.2.239 http://ejbc.kr